<SEC-DOCUMENT>0001193125-21-293288.txt : 20211006
<SEC-HEADER>0001193125-21-293288.hdr.sgml : 20211006
<ACCEPTANCE-DATETIME>20211006165732
ACCESSION NUMBER:		0001193125-21-293288
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20211006
DATE AS OF CHANGE:		20211006

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260097
		FILM NUMBER:		211310273

	BUSINESS ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 489-2100

	MAIL ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d197901ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October&nbsp;6, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH SYSTEMS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name Of Registrant As Specified In Its Charter) </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">06-1245881</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1633 Broadway, Suite 22C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">489-2100</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gerard Michel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delcath Systems, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1633 Broadway, Suite 22C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">489-2100</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copy to: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Veronica
Montagna, Esq. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>McCarter&nbsp;&amp; English, LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>100 Mulberry Street, Four Gateway Center </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Newark, New Jersey 07102 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(973) <FONT STYLE="white-space:nowrap">639-7948</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approximate date of
commencement of proposed sale to the public</B>: From time to time after the effective date of this registration statement as determined by the selling securityholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a
post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that
shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the
following box.&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Securities</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount<BR>to be<BR>registered (1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>maximum<BR>offering price<BR>per unit (2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed |<BR>Maximum<BR>Aggregate<BR>Offering Price (2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee (3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, par value $0.01, issuable upon the conversion
of Series E Convertible Preferred Stock following the conversion of 8% senior secured promissory notes into Series E Convertible Preferred Stock by the selling securityholders named in the prospectus contained herein and any supplements
thereto</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">237,614</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10.32</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">$2,452,176.48</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$227.32</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, par value $0.01, issuable upon the conversion
of up to $3&nbsp;million principal amount of a loan made to the registrant by the selling securityholder named in the prospectus contained heqrein and any supplements thereto</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">250,417</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10.32</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">$2,584,303.44</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$239.56</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, par value $0.01, issuable upon the exercise of
a Warrant issued to the selling securityholder named in the prospectus contained herein and any supplements thereto</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">127,755</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10.32</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">$1,318,431.60</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$122.22</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, par value $0.01, held by selling
securityholders named in the prospectus contained herein and any supplements thereto</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">22,413</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10.32</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">$231,302.16</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$21.44</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">638,199</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10.32</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">$6,586,213.68</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$610.54</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), the shares
of the registrant&#146;s common stock, par value $0.01 (the &#147;Common Stock&#148;), being registered hereunder include such indeterminate number of additional shares of Common Stock as may be issuable as a result of stock splits, stock dividends
or similar transactions with respect to the shares being registered hereunder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated in accordance with Rule 457(c) under the Securities Act solely for the purpose of calculating the
registration fee, based on the average of the high and low prices of shares of the Common Stock on September&nbsp;29, 2021, a date within five business days prior to the filing of this registration statement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registration fee is calculated by multiplying the maximum aggregate offering price of all securities being
registered hereunder by 0.0000927. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The registrant hereby amends this Registration Statement on such date or dates as may be necessary
to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until
the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#cf0a2c"><B>The information in this prospectus is not complete and may be changed. A registration
statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold until the registration statement is effective. This prospectus is not an offer to sell these securities, and we are
not soliciting offers to buy these securities, in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#cf0a2c"><B>SUBJECT TO COMPLETION, PRELIMINARY PROSPECTUS DATED OCTOBER&nbsp;6, 2021 </B></FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197901g14q77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 638,199 Shares of Common Stock Offered by the Selling Stockholders </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading &#147;Selling Stockholders&#148; in
this prospectus, or their assigns (the &#147;Selling Stockholders&#148;), of up to an aggregate of 638,199 shares of our common stock, par value $0.01 per share (&#147;Common Stock&#148;), consisting of (a)&nbsp;up to 237,614 shares of Common Stock
that may be issued to Selling Stockholders upon the conversion of up to an aggregate of 2,376.14 shares of our Series E Convertible Preferred Stock, par value $0.01 per share (the &#147;Series E Preferred Stock&#148;), at a conversion price of
$1,198 per share, following an election by such Selling Stockholders to convert the principal amount of, and all interest accruing under, 8% senior secured promissory notes issued by us to such Selling Stockholders (the principal of which is
$2&nbsp;million and accrued interest of up to $846,667 which as of October 5, 2021 is $344,556) into shares of Series E Preferred Stock, (b)&nbsp;up to an aggregate of 378,172 shares of Common Stock that may be issued to a Selling Stockholder,
consisting of (i) 250,417 shares of Common Stock that may be issued to such Selling Stockholder upon the conversion of up to $3&nbsp;million principal amount of a loan made to us by such Selling Stockholder (the &#147;Loan&#148;) and (ii) 127,755
shares of Common Stock that may be issued to such Selling Stockholder upon the exercise of a warrant for 127,755 shares of our Common Stock issued to such Selling Stockholder in connection with the Loan at an exercise price of $0.01 per share (the
&#147;Warrant&#148;), and (c) 22,413 shares of Common Stock held by Selling Stockholders, all as described in greater detail under the heading &#147;The Offering&#148; in this prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registration of shares of Common Stock covered by this prospectus does not mean that the Selling Stockholders will offer or sell any such shares. The
Selling Stockholders may sell shares of Common Stock covered by this prospectus in a number of different ways and at varying prices. For additional information on the possible methods of sale that may be used by the Selling Stockholders, you should
refer to the section of this prospectus entitled &#147;Plan of Distribution.&#148; The Selling Stockholders may, individually but not severally, be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act of 1933, as amended
(the &#147;Securities Act&#148;), of the shares of Common Stock that they are offering pursuant to this prospectus. The Selling Stockholders will bear all commissions and discounts, if any, attributable to their respective sales of Common Stock
hereunder. We will bear all costs, expenses and fees in connection with the registration of the Common Stock. We will not be paying any underwriting discounts or commissions in this offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the shares of Common Stock sold by the Selling Stockholders hereunder. However, assuming (i)&nbsp;the conversion
of all of the Series E Preferred Stock following an election to convert the principal amount and all accrued interest under the 8% senior secured promissory notes into such shares, (ii)&nbsp;the conversion of the entire convertible portion of the
Loan and (iii)&nbsp;the exercise of the Warrant, we will receive, upon issuance of the Common Stock to the Selling Stockholders $1,278 upon exercise of the Warrant, the outstanding principal amount of the Loan will be reduced by $3&nbsp;million and
the 8% senior secured promissory notes will no longer be outstanding. See &#147;The Offering&#148; and &#147;Use of Proceeds&#148; for more details. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
prospectus supplement may add, update, or change information contained in this prospectus. You should carefully read this prospectus, any applicable prospectus supplement, and the information incorporated by reference in this prospectus and any
applicable prospectus supplement before you make your investment decision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Common Stock is traded on The NASDAQ Capital Market under the symbol
&#147;DCTH.&#148; On October&nbsp;4, 2021, the closing price for our Common Stock, as reported on The NASDAQ Capital Market, was $9.58 per share. Our principal executive offices are located at 1633 Broadway, Suite 22C, New York, New York 10019. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our Common Stock involves a high degree of risk. You should read carefully the risks and uncertainties that are described in (i)&nbsp;the
&#147;<A HREF="#toc197901_6">Risk Factors</A>&#148; section beginning on page 12 of this prospectus, (ii)&nbsp;the &#147;Risk Factors&#148; section of any applicable prospectus supplement or amendment, and (iii)&nbsp;under the &#147;Risk
Factors&#148; or similar headings in our periodic reports and other documents filed with the Securities and Exchange Commission (the &#147;SEC&#148;) that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_3">DESCRIPTION OF THE TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_4">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_5">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_7">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_9">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc197901_13">WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION OF CERTAIN INFORMATION
 BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading &#147;Selling Stockholders&#148; in
this prospectus, or their assigns (the &#147;Selling Stockholders&#148;), of up to an aggregate of 638,199 shares of our common stock, par value $0.01 per share (&#147;Common Stock&#148;), consisting of (a)&nbsp;up to 237,614 shares of Common Stock
that may be issued to Selling Stockholders upon the conversion of up to an aggregate of 2,376.14 shares of our Series E Convertible Preferred Stock, par value $0.01 per share (the &#147;Series E Preferred Stock&#148;), at a conversion price of
$1,198 per share, following an election by such Selling Stockholders to convert the principal amount of, and all interest accruing under, 8% senior secured promissory notes issued by us to such Selling Stockholders (the principal of which is
$2&nbsp;million, and the accrued interest on which as of October 5, 2021 is $344,556) into shares of Series E Preferred Stock, (b)&nbsp;up to an aggregate of 378,172 shares of Common Stock that may be issued to a Selling Stockholder, consisting of
(i) 250,417 shares of Common Stock that may be issued to such Selling Stockholder upon the conversion of up to $3&nbsp;million principal amount of a loan made to us by such Selling Stockholder (the &#147;Loan&#148;) and (ii) 127,755 shares of Common
Stock that may be issued to Such Selling Stockholder upon the exercise of a warrant for 127,755 shares of our Common Stock issued to such Selling Stockholder in connection with the Loan at an exercise price of $0.01 per share (the
&#147;Warrant&#148;), and (c) 22,413 shares of Common Stock held by Selling Stockholders, all as described in greater detail under the heading &#147;The Offering&#148; in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the shares of Common Stock sold by the Selling Stockholders hereunder. However, assuming (i)&nbsp;the conversion
of all of the Series E Preferred Stock following an election to convert the principal amount and all accrued interest under the 8% senior secured promissory notes into such shares, (ii)&nbsp;the conversion of the entire convertible portion of the
Loan and (iii)&nbsp;the exercise of the Warrant, we will receive, upon issuance of the Common Stock to the Selling Stockholders $1,278 upon exercise of the Warrant, the outstanding principal amount of the Loan will be reduced by $3&nbsp;million and
the 8% senior secured promissory notes will be no longer be outstanding. See &#147;The Offering&#148; and &#147;Use of Proceeds&#148; for more details. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we have filed with the Securities and Exchange
Commission, or the SEC, using a shelf registration process. Under this registration statement, the Selling Stockholders may sell Common Stock from time to time in one or more offerings described in this prospectus. This prospectus omits some of the
information contained in the registration statement, and reference is made to the full registration statement for further information with regard to us, the Selling Stockholders and the securities being offered by the Selling Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a description of our Common Stock as well as other information you should know before investing in our Common Stock. Each
time the Selling Stockholders offer and sell our Common Stock hereby, we will provide one or more prospectus supplements or amendments that will contain specific information about the terms of that specific offering of our Common Stock and the
specific manner in which it may be offered. The prospectus supplement or amendment may also add to, update or change any of the information contained in this prospectus. To the extent that any statement we make in a prospectus supplement or
amendment is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus supplement or amendment. You should read both this prospectus and the
applicable prospectus supplement or amendment together with the additional information described under the headings &#147;Where You Can Find More Information&#148; and Incorporation of Certain Information by Reference&#148; before making an
investment decision. This prospectus may not be used to sell our Common Stock unless it is accompanied by a prospectus supplement, or this prospectus is otherwise updated by documents incorporated by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents
for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed or will be filed or incorporated by reference as exhibits to the registration
statement of which this prospectus forms a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information and Incorporation of Certain Information by Reference.&#148; We
urge you to read that registration statement in its entirety, including all amendments, exhibits, schedules and supplements to that registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this prospectus, &#147;Delcath,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;our,&#148; or &#147;us&#148; mean Delcath Systems, Inc. and
its wholly owned subsidiaries. The term &#147;Selling Stockholders&#148; refers, collectively, to the selling stockholders named under the heading &#147;Selling Stockholders&#148; in this prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus summary highlights certain information about us and selected information contained elsewhere in or incorporated by reference into this
prospectus. This prospectus summary is not complete and does not contain all of the information that you should consider before making an investment decision. For a more complete understanding of the Company, you should read and consider carefully
the more detailed information included or incorporated by reference in this prospectus and any applicable prospectus supplement or amendment, including the factors described under the heading &#147;Risk Factors<I>,</I>&#148; beginning on page 12 of
this prospectus, as well as the information incorporated herein by reference, before making an investment decision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of the Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our lead product candidate, the HEPZATO<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, is a drug/device combination product. HEPZATO is
designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO has not been approved for sale in the United States. In Europe, our commercial product is a stand-alone medical
device having the same device components as the HEPZATO KIT but without the melphalan hydrochloride. The device is approved for sale under the trade name CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Hepatic Delivery System for
Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, HEPZATO is
regulated as a combination drug and device by the United States Food and Drug Administration, or the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA&#146;s Center for Drug Evaluation and Research. The FDA has granted
the active moiety melphalan hydrochloride five orphan drug designations for the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and neuroendocrine tumors. The FDA has
granted the active moiety doxorubicin one orphan drug designation for the treatment of patients with hepatocellular carcinoma. In Europe, CHEMOSAT is regulated as a Class&nbsp;IIb medical device and received its CE Mark in 2012. We are
commercializing CHEMOSAT in select markets in the United Kingdom and the European Union, or the EU, where we believe the prospect of securing reimbursement coverage for the use of CHEMOSAT is strongest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced development program is for the use of HEPZATO in the treatment of ocular melanoma liver metastases, or mOM, a type of primary liver cancer.
HEPZATO is being studied in the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma, or the FOCUS Trial, which is a global registration clinical trial that is investigating objective response rate in mOM. The FOCUS Trial is being
conducted at approximately 30 sites in the United States and Europe. The FOCUS Trial initiated treatment on the final enrolled patient on October&nbsp;2, 2020. The primary endpoint of the FOCUS Trial is Objective Response Rate, or ORR, as measured
by RECISTv1.1, in the Intent to Treat (ITT) population. The single arm trial was powered to demonstrate a superior ORR versus checkpoint inhibitors, one of the few mOM treatment categories with a significant amount of peer reviewed publications. The
checkpoint inhibitor ORR was calculated based on a meta-analysis covering 16 different publications which included 476 patients. The pooled overall response rate was 5.5% [95% CI: 3.6, 8.3]. To achieve statistical significance at a 95% Confidence
Interval, the lower bound of the ORR for HEPZATO is required to exceed the 8.3% upper bound of the meta-analysis. Secondary endpoints include Duration of Response, or DOR, Disease Control Rate, or DCR, Overall Survival, or OS, and Progression-Free
Survival, or PFS. Additional exploratory outcome measures include time to objective response, hepatic progression-free survival, hepatic objective response, and quality of life, safety, and other pharmacokinetic measures. Initially, the trial was a
randomized controlled trial which was amended to a single arm trial given slow enrollment due to the rarity of ocular melanoma, absence of crossover to the experimental trial arm, competing clinical trials and the commercial availability of CHEMOSAT
in Europe. Included in the <FONT STYLE="white-space:nowrap">pre-specified</FONT> analyses are comparisons against the Best Alternative Care, or BAC, arm which enrolled 32 patients prior to the amendment to a
<FONT STYLE="white-space:nowrap">single-arm</FONT> trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have paused a global Phase 3 clinical trial of HEPZATO in patients with intrahepatic cholangiocarcinoma,
or the ALIGN Trial, due to difficulties in enrollment. In addition to the FOCUS Trial and the ALIGN Trial, our commercial development plan also includes a registry for CHEMOSAT cases performed in Europe and support of select investigator-initiated
trials, or IITs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver
cancers in order to select a portfolio of indications which will maximize the value of the HEPZATO platform. This may result in a restart of the ALIGN Trial. We believe that the disease states we are investigating and intend to investigate are unmet
medical needs that represent significant market opportunities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Focus Trial Preliminary Analysis</I></B><B>. </B>On March&nbsp;31, 2021, Delcath released a preliminary analysis of the FOCUS trial data based on 87%
of enrolled patients using prespecified analyses. An Independent Review Committee assessed an ORR of 29.2% [95% CI: 20.1, 39.8] in the ITT population, the lower bound of which exceeded the upper bound of the predefined success criteria (8.3%) for
the primary ORR endpoint. In the per protocol populations, evaluable patients in the HEPZATO arm had a statistically significant improvement over BAC in prespecified endpoints including: ORR of 32.9% [95% CI: 22.8, 44.4] versus 13.8% [CI: 3.9, 31.7]
for the BAC arm <FONT STYLE="white-space:nowrap">(Chi-square</FONT> P&lt;0.05), Median PFS of 9.0 months [95% CI: 6.2, 11.8] versus 3.1 months ([95% CI: 2.7, 5.7] for the BAC arm (HR=0.41 p&lt;0.001), and DCR of 70.9% [95% CI: 59.6, 80.6] versus
37.9% [95% CI: 20.7, 57.7] for the BAC arm (p&lt;0.002). In this preliminary analysis, DOR and OS were not yet evaluable. Since not all patients were evaluable for all time points, these preliminary analyses may change as data matures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the HEPZATO safety population of 94 patients, 38 patients (40.4%) experienced a treatment-emergent serious adverse event. The most commonly reported
treatment-emergent serious adverse events were thrombocytopenia (14.9% of patients), neutropenia (10.6% of patients), and leukopenia (4.2% of patients), which were well-manageable. 5% of patients experienced treatment-emergent serious cardiac
adverse events. In all cases the events resolved with no ongoing complications. There were no treatment-related deaths in the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impact of <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> </I></B>The global outbreak of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> a novel strain of coronavirus that causes coronavirus disease <FONT
STYLE="white-space:nowrap">(&#147;COVID-19&#148;),</FONT> has adversely impacted certain areas of the Company&#146;s business. These impacts included a slowing of patient recruitment in the FOCUS Trial and a reduction in the pace at which we can
monitor data at our clinical trial sites.&nbsp;The resulting delay in completing enrollment and additional time required to monitor data caused our announcement for the <FONT STYLE="white-space:nowrap">top-line</FONT> data from our FOCUS Trial to
shift to early 2021 and to be modified to a preliminary analysis.&nbsp;We intend to submit a New Drug Application (&#147;NDA&#148;) to the FDA in the first quarter of 2022 for the treatment of mOM once the FOCUS Trial has been completed.&nbsp;The
ability to achieve this goal is contingent on our ability to monitor data at our clinical sites and, therefore, the timeline may shift as access to the clinical sites changes in response to the rapidly evolving
<FONT STYLE="white-space:nowrap">situation.&nbsp;COVID-19</FONT> has also caused us to experience an increase in volatility in EU commercial product revenue.&nbsp;The results of the FOCUS Trial should also support securing reimbursement coverage for
the use of CHEMOSAT in Europe. Additional impacts of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our business may arise that we are not aware of currently. The ultimate impact of the pandemic on the Company&#146;s results of operations,
financial position, liquidity, or capital resources cannot be reasonably estimated at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Medical Device Directive Transition to Medical
Device Regulation. </I></B>The European Commission recently reviewed the Medical Device Directive legislative framework and promulgated REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5&nbsp;April 2017 on medical devices,
amending Directive 2001/83/EC, Regulation EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. This new Medical Device Regulation became effective on May&nbsp;25, 2017, marking the start of a <FONT
STYLE="white-space:nowrap">3-year</FONT> transition period for manufacturers selling medical devices in Europe to comply with the new medical device regulation, or MDR, which governs all facets of medical devices. The transition task is highly
complex and touches every aspect of product development, manufacturing production, distribution, and post marketing evaluation. As a result of the worldwide <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on April&nbsp;17, 2020, the
European </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parliament adopted the European Commission&#146;s proposal to postpone the implementation of the MDR (EU) 2017/745 by 12 months. This urgently drafted proposal to delay the MDR is in response to
the exceptional circumstances associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the potential impact it may have had on the MDR implementation. The new Date of Application (DoA) for the MDR was May&nbsp;26, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effectively addressing these changes will require a complete review of our device operations to determine what is necessary to comply. We do not believe the
MDR regulatory changes will impact our business at this time, though implementation of the medical device legislation may adversely affect our business, financial condition and results of operations or restrict our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to COVID-related delays experienced by the medical device industry and Notified Bodies (NB) alike, Delcath has not yet achieved MDR certification.
However, our current CE Mark under the Medical Device Directive remains effective until April 2024 and allows us to fully operate, in Europe, accordingly, as Delcath and our Notified Body work closely together through the certification process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in the State
of Delaware in August 1988. Our principal executive offices are located at 1633 Broadway, Suite 22C, New York, New York 10019. Our telephone number is (212) <FONT STYLE="white-space:nowrap">489-2100.</FONT> Our website address is
<U>http://www.delcath.com</U>. Information contained in, or accessible through, our website does not constitute any part of, and is not incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_3"></A>DESCRIPTION OF THE TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Term Loan from Avenue Venture Opportunities Fund, L.P. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2021, we entered into a Loan and Security Agreement and Supplement to Loan and Security Agreement (together, the &#147;Loan Agreement&#148;)
with Avenue Venture Opportunities Fund, L.P. (the &#147;Lender,&#148; or &#147;Avenue Capital&#148;) for a term loan in an aggregate principal amount of up to $20,000,000 (the &#147;Loan&#148;). The Loan bears interest at an annual rate equal to the
greater of (a)&nbsp;the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The Loan is secured by a security interest in all of the Company&#146;s assets. The Loan maturity date is August&nbsp;1, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At closing, the Lender funded the initial $15,000,000 tranche of the Loan (&#147;Tranche 1&#148;), including $4,000,000 which has been funded into a
restricted account and will be released upon achievement of (a)(x) positive FOCUS trial efficacy per the trial&#146;s predefined Statistical Analysis Plan (SAP) (specifically the Overall Response Rate exceeds
<FONT STYLE="white-space:nowrap">the&nbsp;pre-specified&nbsp;threshold</FONT> for success defined in the SAP by a statistically significant amount); and (y)&nbsp;based on data contained within the FOCUS trial database and appropriate for use with
the U.S. Food and Drug Administration, safety and tolerability among FOCUS trial participants is within the range of currently approved and commonly used cytotoxic chemotherapeutic agents; and (b)&nbsp;raising subsequent net equity proceeds of at
least $20,000,000. The Company may request an additional $5,000,000 principal amount (&#147;Tranche 2&#148;) from the Lender between October&nbsp;1, 2022 and December&nbsp;31, 2022, with funding of Tranche 2 subject to approval of Avenue
Capital&#146;s Investment Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Up to $3,000,000 of the principal amount of the Loan outstanding may be converted (the &#147;Loan Conversion&#148;),
at the option of the Lender, into shares of the Company&#146;s common stock at a conversion price of $11.98 per share. The Lender&#146;s right to exercise the Loan Conversion is subject to the Beneficial Ownership Limitation set forth in the Warrant
discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Loan, on August&nbsp;6, 2021, the Company issued to the Lender a warrant (the &#147;Warrant&#148;) to purchase an
Applicable Number of shares of Common Stock at an exercise price per share equal to $0.01, which Warrant is exercisable until August&nbsp;31, 2026. &#147;Applicable Number&#148; means (x) 127,755 shares of Common Stock as of the date the Warrant was
issued <I>plus </I>(y)&nbsp;as of the funding date of Tranche 2, if at all, (A) 8.50% of the funded Tranche 2 <I>multiplied by </I>(B)&nbsp;the <FONT STYLE="white-space:nowrap">five-day</FONT> volume weighted average price per share of Common Stock,
determined as of the end of trading on the last trading day before the funding of Tranche 2. The Warrant may not be exercised by the Lender or other holder thereof (the &#147;Holder&#148;) to the extent that after giving effect to the issuance of
shares of Common Stock after the exercise of the Warrant, the Holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of the Warrant (the &#147;Beneficial Ownership Limitation&#148;). The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loan Agreement requires that the Company prepare and file with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> to
register all of the shares of Common Stock issuable upon the exercise of the Loan Conversion and the Warrant. It is not possible to determine if Tranche 2 or any portion thereof will ever be funded and, therefore, it is not possible to determine the
Applicable Number of shares of Common Stock issuable upon exercise of the Warrant after the funding of Tranche 2. Accordingly, the shares of Common Stock registered hereunder include the 127,755 shares that are now available for issuance upon an
exercise of the Warrant. If and at such time that Tranche 2 of the Loan is funded, the Company will register the additional shares of Common Stock that will become available for issuance upon an exercise of the Warrant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rosalind Convertible Notes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2019, the
Company entered into a note purchase agreement with Rosalind Opportunities Fund I L.P. and Rosalind Master Fund L.P. (together, &#147;Rosalind&#148;), pursuant to which Rosalind agreed to transfer and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surrender to the Company for cancellation, warrants to purchase 5,605 shares of our Common Stock (the &#147;Series D Warrants&#148;) and warrants to purchase 0.1&nbsp;million shares of our Common
Stock (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Series D Warrants&#148;). Under the terms of the note purchase agreement, the Company agreed to sell and issue to Rosalind 8% Senior Secured Promissory Notes (&#147;Convertible
Notes&#148;) in an aggregate principal amount of $2,000,000 secured by a security interest in all assets of the Company and maturing on July&nbsp;15, 2021, in full payment and satisfaction of the purchase price for the Series D Warrants and <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Series D Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transactions contemplated by the note purchase agreement were effective and the
Convertible Notes were issued on July&nbsp;15, 2019, upon the closing of the Company&#146;s July 2019 private placement of Series E convertible preferred stock, par value $0.01 per share (&#147;Series E Preferred Stock) and warrants to purchase
shares of Common Stock, to various investors, including Rosalind (the &#147;July 2019 Private Placement&#148;). Immediately following the closing of the July 2019 Private Placement, the Convertible Notes were amended, pursuant to a note amending
agreement dated as of July&nbsp;15, 2019 between the Company and Rosalind to provide that the outstanding principal amount of the Convertible Notes and any accrued and unpaid interest thereon are convertible, at the option of the holder of the
Convertible Notes, into shares of Series E Preferred Stock at the price of $1,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2021, in connection with the closing of the term
loan between the Company and Avenue Capital, the Company and Rosalind executed a Second Note Amending Agreement to further amend the Convertible Notes by (a)&nbsp;reducing the conversion price of the notes to $1,198 per share of Series E Preferred
Stock; and (b)&nbsp;extending the maturity date of the Convertible Notes to October&nbsp;30, 2024. In addition, in order to induce Avenue Capital to provide the Loan, Rosalind agreed to subordinate (a)&nbsp;all of the Company&#146;s indebtedness and
obligations to the holders of the Convertible Notes and (b)&nbsp;all of the Convertible Note holders&#146; security interest in the Company&#146;s assets, to the Loan and Avenue Capital&#146;s security interest in the Company&#146;s assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of Common Stock registered hereunder include the shares of Common Stock issuable to Rosalind upon any conversion of Series E Preferred Stock held
by Rosalind resulting from the conversion of Convertible Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock Held by Director Roger G. Stoll and Chief Operating Officer John Purpura
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2019, Roger G. Stoll, the Chair of the Company&#146;s Board of Directors, participated in the July 2019 Private Placement and, in connection
therewith, was issued 93 shares of Series E Preferred Stock and a warrant to purchase 4,038 shares of Common Stock. The Series E Preferred Stock and related warrant were issued to Mr. Stoll in lieu of cash compensation owed to him for his services
as a director of the Company in 2018. In May 2020, Mr. Stoll exercised his right to convert his Series E Preferred Stock to Common Stock and, as a result thereof, was issued 9,300 unregistered shares of Common Stock. The shares of Common Stock
registered hereunder include the 9,300 unregistered shares of Common Stock held by Mr. Stoll. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2019, John Purpura, the Company&#146;s current
Chief Operating Officer, participated in the July 2019 Private Placement and, in connection therewith, was issued 65 shares of Series E Preferred Stock and a warrant to purchase 1,083,333 shares of Common Stock. The Series E Preferred Stock and
related warrant were issued to Mr.&nbsp;Purpura in lieu of cash compensation owed to him for his services as an officer of the Company in 2018. In May 2020, Mr.&nbsp;Purpura exercised his right to convert his Series E Preferred Stock to Common Stock
and, as a result thereof, was issued 6,500 unregistered shares of Common Stock. In addition, in May 2020, Mr.&nbsp;Purpura received an additional 6,613 unregistered shares of Common Stock in lieu of a cash bonus due to him for his services as an
officer of the Company in 2019. The shares of Common Stock registered hereunder include the aggregate 13,113 unregistered shares of Common Stock held by Mr.&nbsp;Purpura. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_4"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description
of the material terms of our capital stock included in our Amended and Restated Certificate of Incorporation, as amended (our &#147;Certificate of Incorporation&#148;), and our Amended and Restated
<FONT STYLE="white-space:nowrap">By-Laws&nbsp;(our&nbsp;&#147;By-Laws&#148;).&nbsp;This</FONT> description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our Certificate of Incorporation <FONT
STYLE="white-space:nowrap">and&nbsp;By-Laws,&nbsp;which</FONT> are exhibits to the registration statement of which this prospectus forms a part, and by applicable law. The terms of our common stock and preferred stock may also be affected by
Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40,000,000 shares of common stock, par value $0.01 per share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,000,000 shares of preferred stock, par value $0.01 per share. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is the only class or series of our securities which has been registered under Section&nbsp;12 of the Securities Exchange Act of 1934, as
amended, and is listed on The Nasdaq Capital Market under the symbol &#147;DCTH&#148;. Of the 10,000,000 authorized shares of preferred stock, an aggregate of 52,960 shares are designated as Series E Preferred Stock or Series <FONT
STYLE="white-space:nowrap">E-1</FONT> Preferred Stock. As of October&nbsp;5, 2021, there were outstanding 7,356,289 shares of our common stock and an aggregate of 11,707.21 shares of Series E Preferred Stock and Series
<FONT STYLE="white-space:nowrap">E-1</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;5, 2021, there were 2,475,000 shares of the Company&#146;s common stock
reserved under the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, of which 1,255,250 shares remained available to be issued. As of October&nbsp;5, 2021, we had (a) 3,894,498 shares of common stock issuable upon the exercise of outstanding
warrants, including (i) 1,758,843 Series E and Series <FONT STYLE="white-space:nowrap">E-1</FONT> Warrants, (ii) 1,851,900 Series F Warrants, (iii) 156,000 Series F <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants and (iv) 127,755 shares
of common stock that may be issued upon the exercise of a warrant to Avenue Venture Opportunities Fund, LP at a weighted average exercise price of $9.27 per share and (b) 1,718,249 shares of common stock issuable upon the exercise of outstanding
options with a weighted average exercise price of $11.69 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights.</I></B>&nbsp;Our shares of common stock are entitled to voting rights for the election of directors and for all other matters requiring
stockholder action. Each holder of common stock is entitled to one vote for each share, except as otherwise required by law, and subject to the rights of the holders of preferred stock. The common stock does not have cumulative voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend rights.</I></B>&nbsp;Holders of our common stock are entitled to receive such dividends, if any, as may be declared from time to time by our
board of directors in its discretion out of funds legally available therefor. Holders of common stock share ratably in any dividends declared by our board of directors, subject to any preferential dividend rights of any outstanding preferred stock.
Dividends consisting of shares of common stock may be paid to holders of shares of common stock. We do not intend to pay cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation rights.</I></B>&nbsp;Upon our liquidation or dissolution, the holders of our common stock will be entitled to receive, pro rata, all assets
remaining available for distribution to stockholders after payment of all liabilities and provision for the liquidation of any shares of preferred stock at the time outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Rights and Restrictions</I></B>. Our common stock has no preemptive or other subscription rights, and there are no conversion rights or redemption
or sinking fund provisions with respect to such stock. Our common stock is not subject to redemption by us. Our Certificate of Incorporation and Bylaws do not restrict the ability of a holder of common stock to transfer the stockholder&#146;s shares
of common stock. If we issue shares of common stock under this prospectus, the shares will be <FONT STYLE="white-space:nowrap">fully&nbsp;paid&nbsp;and&nbsp;non-assessable&nbsp;and&nbsp;will&nbsp;not</FONT> have, or be subject to, any preemptive or
similar rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Information.&nbsp;Our common stock is traded on the Nasdaq Capital Market under the symbol
&#147;DCTH&#148;. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar</I></B>. The transfer agent and registrar for our common stock is American Stock
Transfer&nbsp;&amp; Trust Company, LLC </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to issue up to 10,000,000 shares of preferred stock in one or more series and to determine the rights and preferences
of the shares of any such series without stockholder approval, of which 11,707.21 shares of Series E Preferred Stock and <FONT STYLE="white-space:nowrap">Series&nbsp;E-1&nbsp;Preferred</FONT> Stock, or, collectively, the Preferred Stock, is
outstanding as of October&nbsp;5, 2021. Our board of directors may issue preferred stock in one or more series and has the authority to fix the designation and powers, rights and preferences and the qualifications, limitations, or restrictions with
respect to each class or series of such class without further vote or action by the stockholders. The ability of our board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing
a change of control of us or the removal of existing management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with a private placement in July 2019, the Company filed a certificate of
designation of Preferences, Rights and Limitations of Series E Preferred Stock with the Secretary of State of the State of Delaware, or the Delaware SOS, for the purpose of amending its Certificate of Incorporation to classify and designate 40,000
authorized but unissued shares of the Company&#146;s preferred stock as shares of Series E Preferred Stock. The preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends and other distributions,
qualifications and terms and conditions of redemption of the Series E Preferred Stock are set forth in the Certificate of Designation and are described below. The certificate of designation became effective on July&nbsp;11, 2019 upon acceptance for
filing by the Delaware SOS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with a private placement in August 2019, the Company filed a certificate of designation of Preferences, Rights
and Limitations of <FONT STYLE="white-space:nowrap">Series&nbsp;E-1&nbsp;Preferred</FONT> Stock with Delaware SOS, for the purpose of amending its Certificate of Incorporation to classify and designate 12,960 authorized but unissued shares of the
Company&#146;s preferred stock as shares of <FONT STYLE="white-space:nowrap">Series&nbsp;E-1&nbsp;Preferred</FONT> Stock. The preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends and other distributions,
qualifications and terms and conditions of redemption of the <FONT STYLE="white-space:nowrap">Series&nbsp;E-1&nbsp;Preferred</FONT> Stock are set forth in the certificate of designation and are described below. The certificate of designation became
effective on August&nbsp;15, 2019 upon acceptance for filing by the Delaware SOS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion rights.</I></B><B></B>&nbsp;Each share
of the Series E Preferred Stock and <FONT STYLE="white-space:nowrap">Series&nbsp;E-1&nbsp;Preferred</FONT> Stock has a par value of $0.01 per share and a stated value equal to $1,000, or the Stated Value, and is convertible at any time at the option
of the holder into the number of shares of common stock determined by dividing the stated value by the conversion price of $10.00, subject to certain limitations and adjustments, or the Conversion Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights.</I></B><B><I></I></B>&nbsp;The Preferred Stock votes an as converted basis on all matters submitted to the holders of
common stock for approval, subject to certain limitations and exceptions. The affirmative vote of the holders of a majority of the then outstanding shares of Preferred Stock is required to increase the number of authorized shares of Preferred Stock
or to alter or change adversely the powers, preferences or rights given to the Preferred Stock, or to amend the Company&#146;s organizational documents in any manner that adversely affects the rights of the holders of the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend rights.</I></B><B></B>&nbsp;Except for certain adjustments, the holders of Preferred Stock are entitled to receive dividends on
shares of Preferred Stock equal (on an as if converted basis) to and in the same form as dividends paid on shares of the common stock. Any such dividends that are not paid to the holders of Preferred Stock will increase the Stated Value. No other
dividends will be paid on shares of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation rights.</I></B><B><I></I></B>&nbsp;Upon any liquidation of the Company,
the holders of Preferred Stock will be entitled to receive out of the assets of the Company an amount equal to the Stated Value plus any accrued and unpaid dividends thereon for each share of Preferred Stock before any distribution or payment will
be made to the holders of the common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our Certificate of Incorporation and Bylaws could have the effect of making it more difficult for our stockholders to replace management
at a time when a substantial number of stockholders might favor a change in management. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing for a staggered board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorizing the board of directors to fill vacant directorships or increase the size of its board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our board of directors has the authority to issue up to 9,929,890 shares of preferred stock in one or more series and to
determine the rights and preferences of the shares of any such series without stockholder approval. Any series of preferred stock is likely to be senior to the common stock with respect to dividends, liquidation rights and, possibly, voting rights.
The board&#146;s ability to issue preferred stock may have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits Delaware corporations from engaging in a wide range of specified
transactions with any interested stockholder, defined to include, among others, any person other than such corporation and any of its majority owned subsidiaries who own 15% or more of any class or series of stock entitled to vote generally in the
election of directors, unless, among other exceptions, the transaction is approved by (i)&nbsp;our board of directors prior to the date the interested stockholder obtained such status or (ii)&nbsp;the holders
<FONT STYLE="white-space:nowrap">of&nbsp;two-thirds&nbsp;of</FONT> the outstanding shares of each class or series of stock entitled to vote generally in the election of directors, not including those shares owned by the interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board of Directors.</I></B><B><I></I></B>&nbsp;Our Certificate of Incorporation and Bylaws provide that our board of directors
be classified into three classes of directors of approximately equal size. As a result, in most circumstances, a person can gain control of our board only by successfully engaging in a proxy contest at two or more annual meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Shares.</I></B><B><I></I></B>&nbsp;Our authorized but unissued shares of preferred stock are available for
future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, corporate acquisitions, employee benefit plans and stockholder rights plans. The
existence of authorized but unissued and unreserved preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_5"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Issuer</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delcath Systems, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Common Stock offered by the Selling Stockholders</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;Up to<B> </B>237,614 shares that may be issued to Rosalind Opportunities Fund I L.P. and
Rosalind Master Fund L.P. (together, &#147;Rosalind&#148;) upon the conversion of up to an aggregate of 2,376.14 shares of our Series E Convertible Preferred Stock, par value $0.01 per share (the &#147;Series E Preferred Stock&#148;), at a
conversion price of $1,198 per share, following an election by Rosalind to convert into shares of Series E Preferred Stock an aggregate $2,000,000 principal amount of 8% senior secured promissory notes held by Rosalind, including all accrued
interest thereunder, which notes mature and become due and payable by us on October&nbsp;30, 2024. See &#147;Description of the Transactions,&#148; &#147;Selling Stockholders&#148; and &#147;Description of Capital Stock &#150; Series E Preferred
Stockholders&#146; Right to Convert into Common Stock.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;Up to 250,417 shares that may be issued to Avenue Venture Opportunities Fund, L.P. (&#147;Avenue
Capital&#148;) upon Avenue Capital&#146;s election to convert, at a conversion price of $11.98 per share, up to $3,000,000 of the principal amount of a $15,000,000 secured senior term loan (the &#147;Loan&#148;) made by Avenue Capital to the Company
on August&nbsp;6, 2021 pursuant to the terms of a Loan and Security Agreement and Supplement to Loan and Security Agreement (together, the &#147;Loan Agreement&#148;) between the Company and Avenue Capital, which Loan may be increased to $20,000,000
at the request of the Company subject to approval of Avenue Capital. See &#147;Description of the Transactions&#148; and &#147;Selling Stockholders.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;Up to 127,755 shares that may be issued to Avenue Capital upon the exercise of a common stock
warrant (the &#147;Warrant&#148;) issued to Avenue Capital in connection with the Loan pursuant to the Loan Agreement, having an exercise price of $0.01 per share, exercisable until August&nbsp;31, 2026. See &#147;Description of the
Transactions&#148; and &#147;Selling Stockholders.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iv)&#8194;An aggregate of 22,413 shares of Common Stock held by (1)&nbsp;our director Roger Stoll, which shares were
issued to him in lieu of cash compensation owed to him for his service on our board of directors in 2018 and (2)&nbsp;our executive officer, John Purpura, which shares were issued to him in lieu of cash compensation owed to him for his services as
an executive officer in 2018 and 2019, respectively. See &#147;Selling Stockholders.&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Use of Proceeds</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We will not receive any of the proceeds from the shares of Common Stock sold by the Selling Stockholders hereunder. However, assuming (i)&nbsp;the conversion of all of the Series E Preferred Stock following an election to convert
the principal amount and all accrued interest under the 8% senior secured promissory notes into such shares, (ii)&nbsp;the conversion of the entire convertible portion of the Loan and (iii)&nbsp;the exercise of the Warrant, we will receive, upon
issuance of the Common Stock to the Selling Stockholders $1,278 upon exercise of the Warrant, the outstanding principal amount of the Loan will be reduced by $3&nbsp;million and the 8% senior secured promissory notes will be no longer be
outstanding. See &#147;The Offering&#148; and &#147;Use of Proceeds&#148; for more details.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Trading Market and Ticker Symbol for Common Stock</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &#147;DCTH.&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Risk Factors</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investing in our securities involves a high degree of risk. For a discussion of factors to consider before deciding to invest in our Common Stock, you should carefully review and consider the &#147;Risk Factors&#148; section of this
prospectus, as well as the risk factors described or referred to in any documents incorporated by reference in this prospectus, and in any applicable prospectus supplement or amendment.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An investment in our Common Stock involves a high degree of risk. Prior to making a decision about investing in our Common Stock, you should consider
carefully the specific risk factors discussed in the sections entitled &#147;<I>Risk Factors</I>&#148; contained in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, as
filed with the SEC on March&nbsp;31, 2021, which are incorporated in this prospectus by reference in their entirety. Additional risk factors that you should carefully consider may be included in our subsequent filings with the SEC, including a
prospectus supplement or amendment hereto relating to an offering of our Common Stock by us or the Selling Stockholders. The risks and uncertainties described in this prospectus, any applicable prospectus supplement or amendment, and the documents
incorporated by reference herein are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or
uncertainties described in this prospectus, any applicable prospectus supplement or amendment, or the documents incorporated by reference herein actually occur, our business, financial condition, results of operations and cash flow could be
materially and adversely affected. In that case, the trading price of our Common Stock could decline, perhaps significantly, and you might lose part or all of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_7"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, and the documents incorporated by reference herein, contain, or will contain, &#147;forward-looking statements&#148; within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as &#147;intends,&#148; &#147;believes,&#148; &#147;anticipates,&#148; &#147;indicates,&#148; &#147;plans,&#148; &#147;expects,&#148;
&#147;suggests,&#148; &#147;may,&#148; &#147;would,&#148; &#147;should,&#148; &#147;potential,&#148; &#147;designed to,&#148; &#147;will,&#148; &#147;ongoing,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;predict,&#148; &#147;could,&#148;
and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs,
expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Risks that could cause actual results to vary from expected results expressed in our forward-looking
statements include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement of future clinical trials and the results and timing of those clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize CHEMOSAT and HEPZATO, generate revenue and successfully obtain
reimbursement for the procedure and Delcath Hepatic Delivery system; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and results of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations about the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and any disruption or impact
to our operations due to the pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission and timing of applications for regulatory approval and approval thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully source certain components of CHEMOSTAT and HEPZATO and enter into supplier contracts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully manufacture CHEMOSAT and HEPZATO; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate
partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of potential market opportunities and our ability to successfully realize these opportunities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors discussed under the headings &#147;Business,&#148; &#147;Risk Factors&#148; and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended subsequent to our filing of such Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as well as any amendments thereto reflected in subsequent filings with the
SEC, which sections are incorporated by reference. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date the statements are made. Except
as required under the federal securities laws and rules and regulations of the SEC, we undertake no obligation to update or revise forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting
forward-looking information. We caution you not to unduly rely on the forward-looking statements when evaluating the information presented herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the shares of Common Stock sold by the Selling Stockholders hereunder. However, assuming (i)&nbsp;the conversion
of all of the Series E Preferred Stock following an election to convert the principal amount and all accrued interest under the 8% senior secured promissory notes into such shares, (ii)&nbsp;the conversion of the entire convertible portion of the
Loan and (iii)&nbsp;the exercise of the Warrant, we will receive, upon issuance of the Common Stock to the Selling Stockholders $1,278 upon exercise of the Warrant (which will be used for working capital purposes), the outstanding principal amount
of the Loan will be reduced by $3&nbsp;million and the 8% senior secured promissory notes will be no longer be outstanding. We have agreed to pay all costs, expenses and fees relating to the registration of the shares of Common Stock covered by this
prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_9"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders, or each of their donees, pledgees, assignees, transferees or other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> are offering for resale, from time to time, up to an aggregate of 638,199 shares of Common Stock. The shares of Common Stock covered by this
prospectus represent all the shares of Common Stock that have been or may be issued to the Selling Stockholders in connection with the transactions described under the heading &#147;The Offering&#148; on page 11 of this prospectus. The following
table sets forth certain information with respect to beneficial ownership of our Common Stock as of October&nbsp;5, 2021 by the Selling Stockholders, as determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange
Act of 1934, as amended (the &#147;Exchange Act&#148;), prior to this offering and after this offering. This information has been obtained from the Selling Stockholders or in Schedules 13G or 13D and other public documents filed with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock beneficially owned after this offering assumes the sale of all of the Common Stock offered by the Selling Stockholders
pursuant to this prospectus. However, because the Selling Stockholders may sell none, some or all of the shares of Common Stock covered by this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual
number of shares of Common Stock that will be sold by the Selling Stockholders or that will be held by the Selling Stockholders after completion of any sales. We do not know how long the Selling Stockholder will hold the shares of Common Stock
covered by this prospectus before selling them. Information concerning the Selling Stockholders may change from time to time and changed information will be presented in a supplement to this prospectus if and when necessary and required. However,
the Selling Stockholders may sell or transfer all or a portion of their shares of Common Stock covered by this prospectus pursuant to any available exemption from the registration requirements of the Securities Act. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLING STOCKHOLDER&nbsp;TABLE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Investor&nbsp;Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Shares<BR>Beneficially&nbsp;Owned<BR>Prior&nbsp;to&nbsp;Offering(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number&nbsp;of&nbsp;Shares<BR>to&nbsp;be&nbsp;Sold<BR>Pursuant&nbsp;to&nbsp;the<BR>Prospectus(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned&nbsp;After<BR>Offering(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of<BR>Class&nbsp;After<BR>Offering*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avenue Venture Opportunities Fund, L.P. (3)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Avenue Capital Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11 West 42nd Street, 9th Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10036</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rosalind Opportunities Fund I L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rosalind Master Fund L.P. (4)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Rosalind Advisors, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">175 Bloor Street East</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suite 1316, North Tower</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toronto, Ontario</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">M4W 3R8 Canada</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">769,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">840,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Investor&nbsp;Name and Address</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Shares<BR>Beneficially&nbsp;Owned<BR>Prior&nbsp;to&nbsp;Offering(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number&nbsp;of&nbsp;Shares<BR>to&nbsp;be&nbsp;Sold<BR>Pursuant&nbsp;to&nbsp;the<BR>Prospectus(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned&nbsp;After<BR>Offering(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of<BR>Class&nbsp;After<BR>Offering*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roger G. Stoll, Ph.D. (5)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Delcath Systems, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1633 Broadway, Suite 22C</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, New York 10019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Purpura (6)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Delcath Systems, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1633 Broadway, Suite 22C</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, New York 10019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Percentage not listed if less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Beneficial ownership&#148; means that a person, directly or indirectly, has or shares voting or
investment power with respect to a security or has the right to acquire such power within 60 days. The number of shares beneficially owned is determined as of October&nbsp;4, 2021, and the percentage is based upon 7,356,289 shares of our Common
Stock outstanding as of October&nbsp;4, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes sale of all shares of Common Stock covered by this prospectus and no further acquisitions of shares of
Common Stock by the Selling Stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based partially on the Company&#146;s records and, in part, on information provided by Avenue Venture
Opportunities Fund, L.P., consists of (i) 250,417 shares of Common Stock that may be issued to such Selling Stockholder upon the conversion of up to $3&nbsp;million principal amount of the Loan and (ii) 127,755 shares of Common Stock that may be
issued to such Selling Stockholder upon the exercise of the Warrant. The convertible portion of the Loan may not be converted and the Warrant may not be exercised by such Selling Stockholder to the extent that after giving effect to the issuance of
shares of Common Stock after the conversion of the convertible portion of the Loan or the exercise of the Warrant, such Selling Stockholder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of the convertible portion of the Loan or the exercise of the Warrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based partially on the Company&#146;s records and, in part, on information provided in a Statement on Schedule
13D/A jointly filed with the SEC on June&nbsp;25, 2021, by and on behalf of Rosalind Advisors, Inc., Rosalind Opportunities Fund I L.P., Rosalind Master Fund L.P., Steven Salamon and Dr.&nbsp;Gilad Aharon (collectively, &#147;Rosalind&#148;),
Rosalind Advisors, Inc. (advisor to Rosalind Opportunities Fund I L.P. and Rosalind Master Fund L.P.), Mr.&nbsp;Salamon and Dr.&nbsp;Aharon have shared voting power and dispositive power of (i) 421,500 shares of Common Stock, (ii) 1,090,121 shares
of Common Stock issuable upon conversion of 10,901 shares of Series E Preferred Stock, (iii) an aggregate of 198,772 shares of Common Stock issuable upon the conversion of an aggregate 1,988 shares of Series E Preferred Stock, at a conversion rate
of $1,198 per share, following an election by Rosalind Opportunities Fund I L.P. and Rosalind Master Fund L.P. to convert an aggregate $2 million principal amount of 8% senior secured promissory notes issued by the Company to such Selling
Stockholders, together and with all accrued interest thereon into shares of Series E Preferred Stock and (iv)1,253,958 shares of Common Stock issuable upon exercise of warrants (the &#147;Rosalind Warrants&#148;). The foregoing clauses (ii), (iii)
and (iv) indicate the number of share of Common Stock issuable to the Selling Stockholders upon a full conversion of the Series E Preferred Stock and a full exercise of the Rosalind Warrants without giving effect to the Blockers (as defined below).
Pursuant to the terms of (i) the certificate of designations containing the terms of the Series E Preferred Stock, the Selling Stockholders cannot convert the Series E Preferred Stock to the extent that the Selling Stockholders would beneficially
own, after any such conversion, more than 9.99% of the outstanding shares of the Common Stock (the &#147;Preferred Stock Blockers&#148;) and (ii) the Rosalind Warrants, the Selling Stockholders cannot exercise the Rosalind Warrants to the extent
that the Selling Stockholders would beneficially own, after any such exercise, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
more than 4.99% of the outstanding shares of Common Stock (the &#147;Rosalind Warrant Blockers&#148; and collectively with the Preferred Stock Blockers, the &#147;Blockers&#148;). The table
indicates the number of shares of Common Stock beneficially owned by the Selling Stockholders and the percentage ownership of the Selling Stockholders after giving effect to the Blockers. Mr.&nbsp;Salamon and Dr.&nbsp;Aharon are members of the Board
of Directors of the Company pursuant to a Board Appointment Agreement. Mr.&nbsp;Salamon and Dr.&nbsp;Aharon disclaim beneficial ownership with respect to these securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 9,300 shares of Common Stock held by Dr.&nbsp;Stoll, which were issued to Dr.&nbsp;Stoll as equity in
lieu of cash compensation, 4,038 shares of Common Stock which Dr.&nbsp;Stoll has the right to acquire upon exercise of outstanding warrants and 22,804 shares of Common Stock which Dr.&nbsp;Stoll has the right to acquire upon exercise of outstanding
options exercisable within 60 days of October&nbsp;4, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 13,113 shares of Common Stock held by Mr.&nbsp;Purpura, which were issued to Mr.&nbsp;Purpura as
equity in lieu of cash compensation, 2,822 shares of Common Stock which Mr.&nbsp;Purpura has the right to acquire upon exercise of outstanding warrants and 83,241 shares of Common Stock which Mr.&nbsp;Purpura has the right to acquire upon exercise
of outstanding options exercisable within 60 days of October&nbsp;4, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;8, 2020, we entered into a Board Appointment Agreement, dated as of April&nbsp;8, 2020, with Rosalind Opportunities Fund I L.P. and Rosalind
Maser Fund L.P. (&#147;Rosalind&#148;), pursuant to which Steven Salamon and Gil Aharon, who are principals of Rosalind, have been appointed as directors of the Company&#146;s board of Directors. Certain shares of Common Stock registered for resale
hereunder are also held by Roger G. Stoll, who is the Chairman of the Board of Directors of the Company and John Purpura, who serves as the Chief Operating Officer of the Company. Except as a result of the term loan transaction with Avenue Capital
described herein under the heading &#147;Description of the Transactions,&#148; Avenue Capital has not held any position or office with us or any of our predecessors or affiliates within the last three years and has not had a material relationship
with us or any of our predecessors or affiliates within the past three years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the shares of Common Stock issued, or issuable upon the conversion of Series E Preferred Stock, to the Selling Stockholders to permit the
resale of those shares of Common Stock by the holders of the shares of Common Stock from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the shares of Common Stock.
We will bear all fees and expenses incident to our obligation to register the shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may sell all or a portion
of the share of Common Stock beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the Shares are sold through underwriters or broker-dealers, the Selling
Stockholders will be responsible for underwriting discounts or commissions or agent&#146;s commissions. The shares of Common Stock may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted
at the time of sale, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or in transactions otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These
sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling shares of Common Stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares of Common Stock as agent but may position
and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares of Common Stock
at a stipulated price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether such options are listed on an
options exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders also may resell all or a portion of the shares of Common Stock in open market transactions in reliance upon Rule 144 under the
Securities Act, as permitted by that rule, or Section&nbsp;4(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effects such
transactions by selling shares of Common Stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling
Stockholders or commissions from purchasers of the shares of Common Stock for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this
prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 5110. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with sales of the shares of Common Stock, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares in the course of hedging in positions they assume. The Selling Stockholders may also sell shares short and if such short sale shall take place after the date that the registration
statement of which this prospectus is a part is declared effective by the SEC, the Selling Stockholders may deliver the shares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales.
The Selling Stockholders may also loan or pledge shares to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter into option or other transactions with broker-dealers or
other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares of Common Stock offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use shares of Common Stock
registered under the registration statement of which this prospectus is a part to cover short sales of our Common Stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of Common Stock owned by it and, if the
Selling Stockholder defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. A Selling Stockholders also may
transfer and donate its shares of Common Stock in other circumstances in which case the donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> will be
the selling beneficial owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker-dealers or agents that are involved in selling the
shares of Common Stock may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the
shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with
any person to distribute the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder has informed us that it is not a registered broker-dealer and does not have any written or
oral agreement or understanding, directly or indirectly, with any person to distribute the shares of Common Stock. Upon us being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer
for the sale of shares of Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b)
under the Securities Act, disclosing (i)&nbsp;the name of the Selling Stockholder and of the participating broker-dealer(s), (ii) the number of shares of Common Stock involved, (iii)&nbsp;the price at which such shares of Common Stock were sold,
(iv)&nbsp;the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&nbsp;that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in
this prospectus, and (vi)&nbsp;other facts material to the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay certain fees and expenses incurred by us incident to the registration
of the shares of Common Stock hereunder. We have agreed to indemnify Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states, the shares of Common Stock may be sold in such states only through registered or licensed brokers or dealers. In
addition, in some states the shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any other person participating in such distribution will be subject to
applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of Common Stock by the
Selling Stockholders and any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of Common Stock to engage in market-making activities with respect to the shares. All of the
foregoing may affect the marketability of the shares and the ability of any person or entity to engage in market-making activities with respect to the shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of Common Stock to be offered for resale by the Selling Stockholder under this prospectus will be passed upon for us by
McCarter&nbsp;&amp; English, LLP, Newark, New Jersey. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2020 and 2019 and for each of the two years in the period ended December&nbsp;31, 2020
incorporated by reference in this prospectus have been so incorporated in reliance on the report of Marcum, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in
auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc197901_13"></A>WHERE YOU CAN FIND MORE INFORMATION AND INCORPORATION OF CERTAIN INFORMATION BY
REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference into this prospectus the information contained in other documents we file with the SEC, which
means that we can disclose important information to you by referring you to those documents. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded, for
purposes of this prospectus, to the extent that a statement contained in or omitted from this prospectus, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such
statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We incorporate by reference the documents listed below which have been filed by us: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021016962/dcth-10k_20201231.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;31, 2021, including those portions of the Form <FONT STYLE="white-space:nowrap">10-K</FONT> incorporated by
reference from our definitive <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521108254/d153004ddef14a.htm">proxy statement</A> filed with the SEC on April&nbsp;7, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended
(i)&nbsp;March&nbsp;31, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021026362/dcth-10q_20210331.htm">May&nbsp;11, 2021</A> and (ii)&nbsp;June&nbsp;
30, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000156459021043029/dcth-10q_20210630.htm">August&nbsp;10, 2021</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021009590/dcth-8k_20210223.htm">March&nbsp;1,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521104082/d22722d8k.htm">April&nbsp;
1, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521154966/d47677d8k.htm">May&nbsp;
7, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000156459021034909/dcth-8k_20210628.htm">June&nbsp;
29, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/872912/000119312521243492/d179551d8k.htm">August&nbsp;11, 2021</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration on <A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312520128421/d915262d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-Al2B</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-16133)</FONT> filed with the SEC on April&nbsp;30, 2020, including any amendment or report filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any
report or documents that is not deemed filed under such provisions, (1)&nbsp;on or after the date of filing of the registration statement containing this prospectus and prior to the effectiveness of the registration statement and (2)&nbsp;on or
after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed incorporated by
reference in this prospectus and to be a part of this prospectus from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date of filing of those documents and will be automatically updated and, to the extent described above, supersede information contained or incorporated by reference in this prospectus and
previously filed documents that are incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this prospectus shall be deemed to incorporate information
furnished but not filed with the SEC pursuant to Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Upon written or oral request, we will provide without charge to each person, including any beneficial owner, to whom a copy
of the prospectus is delivered a copy of any or all of the reports or documents incorporated by reference herein (other than exhibits to such documents, unless such exhibits are specifically incorporated by reference herein). You may request a copy
of these filings, at no cost, by writing or telephoning us at the following address: Delcath Systems, Inc., 1633 Broadway, Suite 22C, New York, New&nbsp;York 10019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at www.delcath.com. You may access our definitive proxy statements on Schedule 14A, annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and periodic amendments to those reports filed or furnished pursuant
to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be
accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. You should not consider the contents of our website in making an investment decision with respect to our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized any one to provide you with any information that differs from that contained in this prospectus. Accordingly, you should not rely on
any information that is not contained in this prospectus. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet site that contains all reports and other information that we file electronically with the SEC. The address of that website is
www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g197901g14q77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 638,199 Shares of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock Offered by the Selling Stockholders </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized any dealer, salesperson or other person to give any information or represent anything not contained in this prospectus. You must not
rely on any unauthorized information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not offer to sell any securities in any jurisdiction where it is unlawful. Neither the delivery
of this prospectus, nor any sale made hereunder, shall create any implication that the information in this prospectus is correct after the date hereof. </P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B>Item&nbsp;14<B>.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Other Expenses of Issuance and Distribution.</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth various expenses being borne by the Company in connection with the sale and distribution of the securities being registered. All
of the amounts shown are estimates except for the Securities and Exchange Commission Registration Fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 610.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,300.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,775.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,686.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Indemnification of Directors and Officers.</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is incorporated under the laws of the State of Delaware. Section&nbsp;102(b)(7) of Delaware&#146;s General Corporation Law (the &#147;DGCL&#148;)
allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where
the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or
obtained an improper personal benefit. Our amended and restated certificate of incorporation provides for this limitation of liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145
of the DGCL, or Section&nbsp;145, provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such
corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such
person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&#146;s best interests and, with respect to any criminal action or
proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who are, were or are a party to any threatened, pending or completed action or suit by or in the right of the
corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#146; fees) actually and reasonably incurred by such
person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the corporation&#146;s best interests, provided that no
indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action
referred to above, the corporation must indemnify him against the expenses which such officer or director has actually and reasonably incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or
agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or
arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify him under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article SEVENTH of the Company&#146;s amended and restated certificate of incorporation provides that no person serving as a director of the
Company shall be personally liable to the Company or its stockholders for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach of his or her fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or a knowing violation of
law, authorized the payment of a dividend or approved a stock repurchase in violation of the DGCL or obtained an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article EIGHTH of the Company&#146;s amended and restated certificate of incorporation requires the Company to indemnify any person who may be
indemnified by a Delaware corporation pursuant to Section&nbsp;145 of the DGCL in each situation where the Company is permitted to indemnify such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our executive officers and directors pursuant to which we have agreed to indemnify such persons against
all expenses and liabilities incurred or paid by such person in connection with any proceeding arising from the fact that such person is or was an officer or director of our company, and to advance expenses as incurred by or on behalf of such person
in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or
hereafter acquire under any statute, provision of our certificate of incorporation, our bylaws, agreement, vote of stockholders or disinterested directors or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we maintain standard policies of insurance that provide coverage (1)&nbsp;to our directors and officers against loss rising from claims made by
reason of breach of duty or other wrongful act and (2)&nbsp;to us with respect to indemnification payments that we may make to such directors and officers. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Exhibits</I></B><B>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A list of exhibits filed with this registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is set forth on the Exhibit&nbsp;Index and
is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B><I>Undertakings.</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Registrant hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective
Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the
Registration Statement or any material change to such information in the Registration Statement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>, that paragraphs
a(i), a(ii) and a(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or 15(d)
of the Exchange Act that are incorporated by reference in the registration statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any
liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date
the filed prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) Each prospectus required to be filed pursuant
to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(l)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by
Section&nbsp;10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of
sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that
no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or
made in any such document immediately prior to such effective date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The undersigned registrant hereby undertakes that, for purposes of determining
any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report
pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) The undersigned registrant hereby undertakes that: (1)&nbsp;for purposes of determining any liability under the
Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)&nbsp;(1) or (4) or
497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and (2)&nbsp;for the purpose of determining any liability under the Securities Act, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312519254834/d794638dex31.htm">Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&#146;s Registration Statement
 on Form <FONT STYLE="white-space:nowrap">S-1/A</FONT> filed September&nbsp;25, 2019).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312519272633/d822396dex31.htm">Amendment to the Amended and Restated Certificate of Incorporation of the Company dated October&nbsp;
17, 2019 (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on October&nbsp;23, 2019).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312519272633/d822396dex32.htm">Certificate of Correction to Amendment to the Amended and Restated Certificate of Incorporation of the Company dated October&nbsp;
22, 2019 (incorporated by reference to Exhibit 3.2 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on October&nbsp;23, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312519325987/d821924dex31.htm">Amendment to the Amended and Restated Certificate of Incorporation of the Company, effective December&nbsp;
24, 2019 (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on December&nbsp;30, 2019). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312520302715/d81992dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated November&nbsp;
23, 2020 (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on November&nbsp;24, 2020).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000095011600002113/0000950116-00-002113-0004.txt">Amended and Restated <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Company (incorporated by reference to Exhibit 3.2 to Amendment
 No.&nbsp;1 to Company&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;SB-2</FONT></A>).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312519192327/d48059dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock of Company (incorporated by reference
 to Exhibit 3.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed July&nbsp;11, 2019).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312519222897/d794478dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of Series <FONT STYLE="white-space:nowrap">E-1</FONT> Convertible Preferred Stock
 of Company (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;16, 2019).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits 3.1 through 3.8 and Exhibit 10.3.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d197901dex51.htm">Opinion of McCarter&nbsp;&amp; English, LLP* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex101.htm">Loan and Security Agreement, dated August&nbsp;
6, 2021, between Delcath Systems, Inc., as borrower, and Avenue Venture Opportunities Fund, L.P., as lender (incorporated by reference to Exhibit 10.1 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;11,
 2021)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex102.htm">Supplement to the Loan and Security Agreement, dated August&nbsp;
6, 2021, between Delcath Systems, Inc. as borrower, and Avenue Venture Opportunities Fund, L.P., as lender (incorporated by reference to Exhibit 10.2 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;11,
 2021)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex103.htm">Warrant, dated August&nbsp;
6, 2021, issued by Delcath Systems, Inc. to Avenue Venture Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.3 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;11,
2021)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex106.htm">8% Secured Promissory Note, dated July&nbsp;
15, 2019, issued by Delcath Systems, Inc. to Rosalind Opportunities Fund I L.P. (incorporated by reference to Exhibit 10.6 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;11,
2021)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex107.htm">8% Secured Promissory Note, dated July&nbsp;
15, 2019, issued by Delcath Systems, Inc. to Rosalind Master Fund L.P. (incorporated by reference to Exhibit 10.7 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;11, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex105.htm">Note Amending Agreement, dated as of July&nbsp;
15, 2019, between Delcath Systems, Inc. and Rosalind Opportunities Fund I L.P. and Rosalind Master Fund L.P. (incorporated by reference to Exhibit 10.5 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;11,
 2021)</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="84%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/872912/000119312521243492/d179551dex104.htm">Second Note Amending Amendment, dated as of August&nbsp;
6, 2021, between Delcath Systems, Inc. and Rosalind Opportunities Fund I L.P. and Rosalind Master Fund L.P (incorporated by reference to Exhibit 10.4 to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed August&nbsp;11,
 2021)</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d197901dex231.htm">Consent of Marcum, LLP, an Independent Registered Public Accounting Firm.*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d197901dex51.htm">Consent of McCarter&nbsp;&amp; English, LLP (included in Exhibit 5.1).* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#poa">Powers of Attorney (included on the signature page of Part II of this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3).*</FONT> </A></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="poa"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York, on
October&nbsp;6, 2021. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER&nbsp;OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gerard Michel as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> with power of substitution, in any and all capacities, to sign any and all amendments and post-effective amendments to this registration statement, and to
file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> or his substitute or substitutes, may do or cause to be done by virtue thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DELCATH SYSTEMS, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gerard Michel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Gerard Michel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gerard Michel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Gerard Michel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;6, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christine Padula</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christine Padula</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Interim Principal Accounting Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Interim Principal Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;6, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christine Padula</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Roger G. Stoll, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;6, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elizabeth Czerepak</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;6, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Salamon</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Steven Salamon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;6, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John R. Sylvester</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">John R. Sylvester</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;6, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gilad Aharon</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Gilad Aharon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;6, 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d197901dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g197901g40j96.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McCarter&nbsp;&amp;&nbsp;English,&nbsp;LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Four
Gateway Center</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Mulberry Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Newark,&nbsp;NJ
07102-4056</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.mccarter.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;6, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath
Systems, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1633 Broadway, Suite 22C </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Delcath Systems, Inc. Shelf Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Delcath Systems, Inc., a Delaware corporation (the &#147;Company&#148;), in connection with the Company&#146;s
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;Registration Statement&#148;) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the
&#147;Act&#148;). The Registration Statement relates to the offer and sale by the selling stockholders identified therein (the &#147;Selling Stockholders&#148;) of up to 638,199 shares of the Company&#146;s common stock, par value $0.01 per share
(&#147;Common Stock&#148;), consisting of (a)&nbsp;up to 237,614 shares of Common Stock that may be issued to Selling Stockholders upon the conversion of an aggregate of up to 2,376.14 shares of the Company&#146;s Series E Convertible Preferred
Stock, par value $0.01 per share (the &#147;Series E Preferred Stock&#148;), at a conversion price of $1,198 per share, following an election by such Selling Stockholders to convert the principal amount of, and all interest accruing under, 8% senior
secured promissory notes issued by the Company to such Selling Stockholders (the principal of which is $2&nbsp;million, and the accrued interest on which as of the date hereof is $344,556) into shares of Series E Preferred Stock, (b)&nbsp;up to an
aggregate of 378,172 shares of Common Stock that may be issued to a Selling Stockholder, consisting of (i) 250,417 shares of Common Stock that may be issued to such Selling Stockholder upon the conversion of up to $3&nbsp;million principal amount of
a loan made to the Company by such Selling Stockholder (the &#147;Loan&#148;) and (ii) 127,755 shares of Common Stock that may be issued to such Selling Stockholder upon the exercise of a warrant for 127,755 shares of the Company&#146;s Common Stock
issued to such Selling Stockholder in connection with the Loan at an exercise price of $0.01 per share (the &#147;Warrant&#148;), and (c) 22,413 shares of Common Stock held by Selling Stockholders (collectively, the &#147;Offering Shares&#148;),
which Offering Shares may be sold from time to time pursuant to Rule 415 under the Act. This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion letter, we have examined the following: (i)&nbsp;the Registration Statement, including the exhibits
thereto, (ii)&nbsp;the Amended and Restated Certificate of Incorporation of the Company, as amended, as certified by the Secretary of the State of Delaware and as certified by the Secretary of the Company (the &#147;Certificate of
Incorporation&#148;), (iii) the Amended and Restated Bylaws of the Company as currently in effect and as certified by the Secretary of the Company, (iv)&nbsp;a copy of certain resolutions of the Board of Directors of the Company, adopted on
August&nbsp;5, 2021, relating to the registration of the Securities, as certified by the Secretary of the Company and (v)&nbsp;such other documents, records and other instruments as we have deemed appropriate for purposes of the opinions set forth
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such examination, we have assumed (i)&nbsp;the Registration Statement and any amendments thereto (including post-effective
amendments) will have become effective; (ii)&nbsp;the Offering Shares will be offered and sold in compliance with applicable federal and state </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">October&nbsp;6, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"> Page&nbsp;
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities laws and in the manner specified in the Registration Statement and any applicable prospectus supplement to the Prospectus; (iii)&nbsp;the genuineness of all signatures; (iv)&nbsp;the
legal capacity of all natural persons; (v)&nbsp;the authenticity of all documents submitted to us as originals; and (vi)&nbsp;the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the
authenticity of the originals of such latter documents. As to all questions of fact material to these opinions that have not been independently established, we have relied upon certificates or comparable documents of officers and representatives of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, and subject to the qualifications stated herein, we are of the opinion that (i)&nbsp;the 22,413
Offering Shares currently outstanding are duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> and (ii)&nbsp;the remaining Offering Shares, when issued in accordance with the terms of the
Certificate of Incorporation and upon conversion of the Series E Preferred Stock and the convertible portion of the Loan and the exercise of the Warrant in accordance with its terms, will be duly authorized, validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration
Statement and the reference to us under the caption &#147;Legal Matters&#148; in the Prospectus. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act
or the rules and regulations of the Securities and Exchange Commission promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion is limited to the Delaware
General Corporation Law. We express no opinion as to the effect of the law of any other jurisdiction. Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other
matters relating to the Company, the Offering Shares or the Registration Statement. No opinion is expressed herein with respect to the qualification of the Offering Shares under the securities or blue sky laws of any state or any foreign
jurisdiction. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>/s/ McCarter&nbsp;&amp; English, LLP</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">McCarter&nbsp;&amp; English, LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d197901dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement of Delcath Systems, Inc. and Subsidiaries on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> of our report dated March&nbsp;31, 2021, which includes an explanatory paragraph as to the Company&#146;s ability to continue as a going concern, with respect to our audits of the consolidated financial
statements of Delcath Systems, Inc.<B> </B>as of December&nbsp;31, 2020 and 2019 and for the years then ended appearing in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Delcath Systems, Inc.<B> </B>for the year ended
December&nbsp;31, 2020. We also consent to the reference to our firm under the heading &#147;Experts&#148; in the Prospectus, which is part of this Registration Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Marcum <SMALL>LLP</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Marcum <SMALL>LLP</SMALL></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New York, NY</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">October&nbsp;5, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g197901g14q77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197901g14q77.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N:4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0&&            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M    7P   2,          0                         !
M  $C    7P                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    7P    !29VAT;&]N9P   2,    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   %\     4F=H
M=&QO;F<   $C     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MK'N96]U;R;/H^E]+_2(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=J[NL8N[DE.L(,8-3'.:\=HQZN1,:NI$)-NG&2*BS5A:JH^ $S2-9>O$#-%
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MF<0!01WV#B'@5-@^8$$=OGT55K$2:-0"+^DF/DQ'>X..$TP3_>K8S9NG(D<
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M4]M; N^=WTBNR24)48S],8V1)P)"F58NFSB#;PB;@JAC(>LM-!'&4W.F]41
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M7J6G\8??_2<.J<?=/S.-83^G./\ >$?Y<.K1_P#IZG_;_P":X@I_U-/Y/^C
ME3\(O[TOX;3J+5_@G[_F<2T_BC_M/ZX%G^^?_/\ PT.JG.?1E_\ N;\J>#+_
M  C_ ,_Q8\G_ $1?_/\ _/U+?@?_ (/T.!)_"/S^HQJB_==?O'^2;]1/Y/\
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<Z#_E_)<;POR#]P?Z=+ \5Z6%CW2PL>Z6%C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g197901g40j96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g197901g40j96.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MOK9KMHY(IHT.#N9<$_[77DC-9VE&TF+5:GDGPFUZ'PUXGOM+U1A:B[ C+2'
M25"< ^G5A]<5U5X\T4T:25T>R^(_%&E^%],^W:A-\I("1I@O)G^Z,\^M<D(.
M;LC-*YPOQ ^);6>A:=)X:N%/]H!V^T[>452 0 >C9/?IBMJ5&[?-T*C'N<WX
MF\%ZQ:^!YM>UCQ3/=RE(W^S%F9#N9>-Q;G&<\#M6D*D7/EBAIJ]D0Z?_ ,D
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M_P!#%=.)^%%SV)?CK_R%](_ZX/\ ^A"EAMF$"M\51;6VM^'[FQF=-7^S1,0
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MCE0.C#!!% &))X4LWD+)+*B_W<@XH T;#2[73E/D)\YZNW)- %V@ H * "@
MH * "@ H * "@#'USPKH?B01_P!KZ?'<M']QLLK >FY2#CVJXSE#9C3:,7_A
M5/@K_H"_^3,W_P 75^VJ=Q\S.FTO2K#1;%++3;5+:W3HB#OZD]2?<UDY.3NR
;=RY2 * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
